Investor Presentation

Attractive market fundamentals | Leadership and scale | Multiple growth drivers Margin improvement | Attractive financial outlook | Compelling sustainability story D Partner of choice status reaffirmed with recent agreement with Samsung Bioepis Just EVOTEC BIOLOGICS Pipeline expansion through partnership to develop and manufacture multiple Biosimilars Numerous opportunities for future collaborations Approximately 120 biologics are expected to lose exclusivity by 20301 polpharma biologics SAMSUNG BIOEPIS Exclusive agreement to commercialize TyrukoⓇ worldwide, with close collaboration up to launch Exclusive agreement to commercialize biosimilar ustekinumab in Europe and North America Around 40 blockbuster drugs to face LoE by 20301 Biosimilars market size is expected to grow from USD 23bn in 2022 to USD 122bn by 20312 Note: The third-party trademarks above are property of their respective owners 1. Based on Evaluate Pharma's data as of February 2023. Blockbustrer drugs considered with > USD 1 billion LoE-1 sales 2. Based on Company analysis using IQVIA Analytics Link MAT12-2022 data in LCUSD at gross price, excludes certain sizeable markets with no or limited Sandoz operations; 2022-2031 CAGR for Biocomparable, Early Entry Generics and Generics as defined by IQVIA and includes all ATC and NFC forms. 15 Management Presentation

View entire presentation